| Iron overload in thalassemia: different organs at different rates AT Taher, AN Saliba Hematology 2014, the American Society of Hematology Education Program Book …, 2017 | 343 | 2017 |
| Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions AN Saliba, AR Harb, AT Taher Journal of blood medicine, 197-209, 2015 | 142 | 2015 |
| Non-transfusion-dependent thalassemia: an update on complications and management J Sleiman, A Tarhini, R Bou-Fakhredin, AN Saliba, MD Cappellini, ... International journal of molecular sciences 19 (1), 182, 2018 | 80 | 2018 |
| Impact of Resident Involvement in Surgery (IRIS-NSQIP): looking at the bigger picture based on the American College of Surgeons-NSQIP database AN Saliba, AT Taher, H Tamim, AR Harb, A Mailhac, A Radwan, ... Journal of the American College of Surgeons 222 (1), 30-40, 2016 | 67 | 2016 |
| Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia AN Saliba, AJ John, SH Kaufmann Cancer Drug Resistance 4 (1), 125, 2021 | 51 | 2021 |
| Thalassaemia in children: from quality of care to quality of life A Amid, AN Saliba, AT Taher, RJ Klaassen Archives of disease in childhood 100 (11), 1051-1057, 2015 | 42 | 2015 |
| Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia AN Saliba, F El Rassi, AT Taher Expert review of hematology 9 (2), 151-168, 2016 | 39 | 2016 |
| Preoperative INR and postoperative major bleeding and mortality: a retrospective cohort study H Tamim, M Habbal, A Saliba, K Musallam, M Al-Taki, J Hoballah, ... Journal of thrombosis and thrombolysis 41, 301-311, 2016 | 35 | 2016 |
| Hemoglobin level and morbidity in non-transfusion-dependent thalassemia AT Taher, KM Musallam, AN Saliba, G Graziadei, MD Cappellini Blood cells, molecules & diseases 55 (2), 108-109, 2015 | 35 | 2015 |
| Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients N Gangat, O Karrar, M Iftikhar, K McCullough, IM Johnson, M Abdelmagid, ... American journal of hematology 99 (2), 193-202, 2024 | 32 | 2024 |
| Outcomes of TP53 mutated AML with evolving frontline therapies: impact of allogeneic stem cell transplantation on survival MD Patel, Y Abaza, JP Bewersdorf, AN Saliba, GSDC Correia, A Duvall, ... | 32 | 2022 |
| PARP inhibitors and myeloid neoplasms: a double-edged sword CM Csizmar, AN Saliba, EM Swisher, SH Kaufmann Cancers 13 (24), 6385, 2021 | 31 | 2021 |
| Association of a remote patient monitoring (RPM) program with reduced hospitalizations in cancer patients with COVID-19 JC Pritchett, BJ Borah, AP Desai, Z Xie, AN Saliba, K Leventakos, ... JCO Oncology Practice 17 (9), e1293-e1302, 2021 | 31 | 2021 |
| Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the … T Badar, E Atallah, R Shallis, AN Saliba, A Patel, JP Bewersdorf, J Grenet, ... Leukemia 37 (4), 799-806, 2023 | 24 | 2023 |
| Factors impacting quality of life in thalassemia patients; results from the Intercontinenthal collaborative study A Amid, R Leroux, M Merelles-Pulcini, S Yassobi, AN Saliba, R Ward, ... Blood 128 (22), 3633, 2016 | 24 | 2016 |
| Morbidities in non‐transfusion‐dependent thalassemia AN Saliba, AT Taher Annals of the New York Academy of Sciences 1368 (1), 82-94, 2016 | 24 | 2016 |
| Thalassemia in the emergency department: special considerations for a rare disease AN Saliba, A Atoui, M Labban, H Hamade, R Bou-Fakhredin, A Mufarrij, ... Annals of Hematology 99, 1967-1977, 2020 | 21 | 2020 |
| Serum ferritin values between 300 and 800 ng/mL in nontransfusion‐dependent thalassemia: A probability curve to guide clinical decision making when MRI is unavailable AN Saliba, KM Musallam, MD Cappellini, G Graziadei, S Daar, ... American journal of hematology 92 (3), E35-E37, 2017 | 21 | 2017 |
| Combination of sorafenib, vorinostat and bortezomib for the treatment of poor-risk AML: Report of two consecutive clinical trials H Sayar, LD Cripe, AN Saliba, MA Zaid, H Konig, HS Boswell Leukemia Research 77, 30-33, 2019 | 20 | 2019 |
| Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study Z Xie, A Nanaa, AN Saliba, R He, D Viswanatha, P Nguyen, D Jevremovic, ... Blood cancer journal 11 (3), 43, 2021 | 19 | 2021 |
